CIBINQO 100 MG
ABROCITINIB : 100 MG · DIN 02528371 · PFIZER CANADA ULC
Health Canada status: MARKETED
What is CIBINQO?
CIBINQO 100 MG contains ABROCITINIB : 100 MG. It is listed in the Health Canada Drug Product Database under DIN 02528371, held by PFIZER CANADA ULC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 29-Sep-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CIBINQO used for?
Treatment of patients 12 years and older with refractory moderate to severe atopic dermatitis, including relief of pruritus, who had inadequate response to other systemic drugs.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02528371 |
|---|---|
| Brand name | CIBINQO |
| Generic / active ingredient | ABROCITINIB : 100 MG |
| Manufacturer | PFIZER CANADA ULC |
| Strength | 100 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | D11AH08 ABROCITINIB |
| AHFS class | 90:24.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 29-Sep-2022 |
| Original market date | 2022-09-29 00:00:00 |
How is it administered?
100 mg or 200 mg orally once daily. Swallow whole; do not crush, split, or chew. Can be taken with or without food (food may improve nausea). Dose reduction required for renal impairment.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (Section 11 header present but content truncated), though typically room temperature.
How is it supplied?
Bottles of 30 tablets.
Contraindications
Hypersensitivity to abrocitinib or any ingredient in the formulation.
Warnings and precautions
Serious infections (viral, bacterial, fungal), malignancies (lymphoma, lung cancer), thrombosis (DVT, PE), and Major Adverse Cardiovascular Events (MACE). Monitor lipids and CBC.
What can be used instead?
Other Canadian products sharing ATC code D11AH08 ABROCITINIB. 3 of 3 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CIBINQO | 200 MG | TABLET | PFIZER CANADA ULC | MARKETED | DIN 02528398 |
| CIBINQO | 50 MG | TABLET | PFIZER CANADA ULC | MARKETED | DIN 02528363 |
Who else supplies ABROCITINIB worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ABROCITINIB appears in 35 registered pack listings across 11 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.